# Andrew ElBardissi

> Andrew ElBardissi is a Series C investor at Deerfield backing Medical. See 14 investments, check sizes, portfolio and contact details. Updated Sep 2026.

- Type: Angel Investor
- Fund: [Deerfield](https://shizune.co/investors/profile/deerfield)
- Location: New York, United States
- Total investments: 14
- Last investment: Feb 2024
- Lead investor: 86%
- Last updated: Sep 2026
- LinkedIn: https://www.linkedin.com/in/aelbardissi

Andrew ElBardissi is a Series C investor at Deerfield in New York focused on Medical and Biotechnology. Andrew ElBardissi - Partner @ Deerfield

## Contacts

5 contacts available for Andrew ElBardissi: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/andrew-elbardissi?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 7 | 50% |
| Biotechnology | 7 | 50% |
| Health Care | 6 | 43% |
| Medical Device | 4 | 29% |
| Health Diagnostics | 2 | 14% |

16 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 6 | 43% |
| Series A | 2 | 14% |
| Venture - Series Unknown | 2 | 14% |
| Series B | 1 | 7% |
| Series G | 1 | 7% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 8 | 57% |
| Israel | 2 | 14% |
| Italy | 1 | 7% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| MMI | We believe that all patients deserve the most innovative, open surgical treatment options so they can live their fullest lives. We’re on a mission to advance robotic technology that pushes the limits of soft tissue open surgery and opens new opportunities for surgeons to restore quality of life for more patients with complex conditions. TheSymani® Surgical System is a first-of-its kind robotic technology that uniquely addresses the scale and complexities of microsurgery and supermicrosurgery to restore quality of life for more patients. | $110M | Series C | Feb 21, 2024 | http://www.mmimicro.com/ |
| Bitterroot Bio | Bitterroot Bio leverages the power of immunotherapy to develop and deliver novel medicines for cardiovascular disease. | $145M | Series A | Jun 07, 2023 | https://brbio.com |
| Epic Sciences | Epic Sciences is a privately held diagnostics company committed to improving cancer management by providing easily accessible and real-time biopsy material to guide personalized medicine. Epic is founded on a powerful platform to identify and characterize rare cells including circulating tumor cells ("CTCs"). Epic is working with anumber of partners including numerous pharmaceutical companies, major cancer centers, the National Cancer Institute, and the National Institutes of Health. | $24M | Series G | Apr 14, 2023 | http://www.epicsciences.com |
| Pleno | Pleno Inc. is a multi-omic instrument platform company democratizing biological target detection for clinical testing and biomedical research. The company’s proprietary Hypercoding™ technology leverages signal processing techniques from the telecommunications industry to deliver targeted biological information at unprecedented scale, precision, andperformance. | $40M | Series A | Oct 12, 2022 | https://plenoinc.com |
| MMI | We believe that all patients deserve the most innovative, open surgical treatment options so they can live their fullest lives. We’re on a mission to advance robotic technology that pushes the limits of soft tissue open surgery and opens new opportunities for surgeons to restore quality of life for more patients with complex conditions. TheSymani® Surgical System is a first-of-its kind robotic technology that uniquely addresses the scale and complexities of microsurgery and supermicrosurgery to restore quality of life for more patients. | $75M | Series B | Jul 20, 2022 | http://www.mmimicro.com/ |
| Aurion Biotechnologies | Based in Seattle, Boston and Tokyo, Aurion Biotech is a clinical-stage biotech company. Our mission is to cure leading forms of blindness and transform the lives of millions of patients, by developing a platform of advanced therapies to treat ocular diseases. Our first candidate is for the treatment of corneal edema, and one of the first clinicallyvalidated cell therapies for corneal care. Healthy cells from a donor cornea are cultured in a novel, multi-step, proprietary and patented process. Cells from a single donor can be used to treat more than 100 recipient eyes. In clinical trials in Japan, patients have experienced significant and durable improvements in key measures of corneal health: visual acuity, corneal endothelial cell density and corneal thickness. | $120M | Venture - Series Unknown | Apr 12, 2022 | https://aurionbiotech.com/ |
| V-Wave | V-Wave Ltd. is a privately held company with offices in Israel and the US. The company is focused on developing percutaneous implantable devices for treating patients with Chronic Heart Failure (HF). V-Wave’s vision is to help patients who remain with disabling symptoms or need hospitalization despite optimized medical treatment. V-Wave hasdeveloped a proprietary interatrial shunt intended to relieve symptoms, reduce hospitalization, increase exercise capacity and improve the overall quality of life.The original concept and development started in Israel with a talented team of engineers and medical scientists. The company’s senior management has decades of experience successfully developing, clinically testing and bringing to market multiple implantable cardiovascular devices. | $98M | Series C | Dec 16, 2021 | http://vwavemedical.com/ |
| Encodia | Encodia provides in-depth information on cellular processes to enable personalized medicine.Our technology reverse translates peptide sequence information into a DNA library. This means scientists can scale their research more easily to accelerate novel approaches to our most challenging diseases.Encodia was established on January 1, 2015 inSan Diego, California. | $75M | Series C | Jan 27, 2021 | https://www.encodia.com/ |
| V-Wave | V-Wave Ltd. is a privately held company with offices in Israel and the US. The company is focused on developing percutaneous implantable devices for treating patients with Chronic Heart Failure (HF). V-Wave’s vision is to help patients who remain with disabling symptoms or need hospitalization despite optimized medical treatment. V-Wave hasdeveloped a proprietary interatrial shunt intended to relieve symptoms, reduce hospitalization, increase exercise capacity and improve the overall quality of life.The original concept and development started in Israel with a talented team of engineers and medical scientists. The company’s senior management has decades of experience successfully developing, clinically testing and bringing to market multiple implantable cardiovascular devices. | $28M | Series C | Sep 22, 2020 | http://vwavemedical.com/ |
| GeneDx | Sema4 is a patient-centered health intelligence company dedicated to advancing healthcare through data-driven insights. Sema4 is transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories.Centrellis™, our innovative health intelligence platform, is enabling us to generate a more complete understanding of disease and wellness and to provide science-driven solutions to the most pressing medical needs. Sema4 believes that patients should be treated as partners, and that data should be shared for the benefit of all. | $121M | Series C | Jul 29, 2020 | https://sema4.com |

10 of 14 investments shown.

## Co-investors
- [Google Ventures](https://shizune.co/investors/profile/google-ventures) — VC Fund, 5 deals together
- [Aperture Venture Partners](https://shizune.co/investors/profile/aperture-venture-partners) — VC Fund, 3 deals together
- [BioStar Capital](https://shizune.co/investors/profile/biostar-private-equity) — VC Fund, 3 deals together
- [BRM Capital](https://shizune.co/investors/profile/brm-capital) — VC Fund, 3 deals together
- [Endeavour Vision](https://shizune.co/investors/profile/endeavour-vision) — VC Fund, 3 deals together
- [Israel Secondary Fund (ISF)](https://shizune.co/investors/profile/israel-secondary-fund-isf) — VC Fund, 3 deals together

## About Deerfield

VC Fund · New York, United States

Deerfield is an investment management firm. They provide a healthcare ecosystem through information and investment. They also provide private and public investments across the life science, medical device, diagnostic, digital health, and health service industries.

5 contacts available at Deerfield.

| Name | Title | Profile |
| --- | --- | --- |
| Alexander Karnal | Partner and Managing Director | https://shizune.co/investors/profile/alex-karnal |
| Andrew ElBardissi | Partner | https://shizune.co/investors/profile/andrew-elbardissi |
| Bryan Sendrowski | Partner | https://shizune.co/investors/profile/bryan-sendrowski |
| Cameron Wheeler | Principal | https://shizune.co/investors/profile/cameron-wheeler |
| Elise Wang | Partner, Head of Private Equity Capital Markets | https://shizune.co/investors/profile/elise-wang |

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Andrew ElBardissi invest in?

Andrew ElBardissi invests primarily in Medical, Biotechnology and Health Care startups, most often at Series C and Series A stage. Most of the 14 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Andrew ElBardissi?

Public channels for Andrew ElBardissi include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Andrew ElBardissi last invest?

The most recent investment recorded for Andrew ElBardissi closed in Feb 2024. Shizune tracks 14 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co